TriangleNCT01006980 · OUTCOME
Time to Confirmed Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- From randomization (initiated January 2010) until December 30, 2010.
What was measured
Time to response was defined as the time from randomization to confirmed response (complete response or partial response).
Analysis population: The analysis population included all participants randomized by September 22, 2010 and with a best overall confirmed response of complete response or partial response.
Groups in this outcome
Vemurafenib
Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).
Dacarbazine
Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).
| Group | Source count |
|---|---|
| Vemurafenib | 106 |
| Dacarbazine | 12 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Vemurafenib | 1.45 | Not reported | 1.0 | 5.5 | Not reported |
| Dacarbazine | 2.72 | Not reported | 1.6 | 5.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.0
- upper Limit
- 5.5
- value
- 1.45
- group Id
- OG001
- lower Limit
- 1.6
- upper Limit
- 5.8
- value
- 2.72
- denoms
- counts
- group Id
- OG000
- value
- 106
- group Id
- OG001
- value
- 12
- units
- Participants
- description
- Time to response was defined as the time from randomization to confirmed response (complete response or partial response).
- dispersion Type
- Full Range
- groups
- description
- Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).
- id
- OG000
- title
- Vemurafenib
- description
- Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).
- id
- OG001
- title
- Dacarbazine
- param Type
- MEDIAN
- population Description
- The analysis population included all participants randomized by September 22, 2010 and with a best overall confirmed response of complete response or partial response.
- reporting Status
- POSTED
- time Frame
- From randomization (initiated January 2010) until December 30, 2010.
- title
- Time to Confirmed Response
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice